【摘要】 目的比较埃克替尼与厄洛替尼分别联合放疗治疗老年Ⅲ期肺腺癌的临床疗效和安全性。方法研究对象为方便选取该院2012年10月—2017年12月治疗的120例老年Ⅲ期肺腺癌患者,随机将所有研究对象分为两组,分别为埃克替尼组及厄洛替尼组,每组60例,评估两组患者的临床疗效及不良反应发生情况。结果埃克替尼组有效率ORR为51.7%,疾病控制率为DCR为85.0%,中位PFS (12.8±0.511)个月,厄洛替尼组有效率ORR为46.7%,疾病控制率为DOR为76.7%,中位PFS (9.1±0.861)个月,两组比较差异有统计学意义(χ~2=4.561,χ~2=5.242,t=4.513,P<0.05);埃克替尼与厄洛替尼组的不良反应,主要表现为皮疹、腹泻、ALT和(或)AST升高等,两组比较差异无统计学意义(P>0.05)。结论埃克替尼联合放疗治疗老年Ⅲ期肺腺癌的临床疗效显著高于厄洛替尼联合放疗,同时埃克替尼联合放疗与厄洛替尼联合放疗不良反应相似。更多还原

【Abstract】 Objective To compare the clinical efficacy and safety of Icotinib hydrochloride and pemetrexed in the treatment of old-age type Ⅲ lung adenocarcinoma. Methods Convenient select 120 patients with advanced lung adenocarcinoma who were treated in hospital from October 2012 to Dceember 2017 were randomly divided into two groups, the Icotinib group and Erlotinib group. Results The effective ORR of the ectatinib group was 51.7%, the disease control rate was 85.0%, the median PFS was(12.8±0.511) months, the erlotinib group had an effective ORR of 46.7%, and the disease control rate was76.7%. The median PFS was(9.1 ±0.861)months, and the difference between the two groups was statistically significant(χ~2=4.561, χ~2=5.242, t=4.513, P<0.05). The adverse reactions of ectinib and erlotinib group were mainly manifested for rash,diarrhea, ALT and/or AST elevation, there was no significant difference between the two groups(P>0.05). Conclusion The clinical efficacy of Icotinib combined with cisplatin in the treatment of EGFR mutant stage Ⅲ lung adenocarcinoma is significantly higher than that of Erlotinib plus cisplatin. Icotinib combined with cisplatin is not compatible with Erlotinib plus cisplatin, which is less reaction and higher safety.更多还原